Abstract
Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.
| Original language | English |
|---|---|
| Pages (from-to) | 229-232 |
| Number of pages | 4 |
| Journal | International Journal of Health Policy and Management |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2020 |
Bibliographical note
Publisher Copyright:© 2020 The Author(s).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 10 Reduced Inequalities
Keywords
- Antiviral Therapy
- Ethiopia
- Hepatitis C
- Out-of-Pocket Expenses
- USA
Fingerprint
Dive into the research topics of '“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver